McNeel D[au] - Search Results

Year	Number of Results
1968	3
1969	2
1970	1
1972	1
1982	1
1991	1
1995	1
1999	1
2000	4
2001	3
2002	1
2003	2
2004	3
2005	6
2006	5
2007	11
2008	3
2009	6
2010	7
2011	12
2012	11
2013	8
2014	4
2015	2
2016	12
2017	11
2018	8
2019	6
2020	7
2021	5
2022	6

1

Androgen deprivation and immunotherapy for the treatment of prostate cancer.

Gamat M, McNeel DG. Gamat M, et al. Among authors: mcneel dg. Endocr Relat Cancer. 2017 Dec;24(12):T297-T310. doi: 10.1530/ERC-17-0145. Epub 2017 Aug 16. Endocr Relat Cancer. 2017. PMID: 28814451 Free PMC article. Review.

2

Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.

England CG, Ehlerding EB, Hernandez R, Rekoske BT, Graves SA, Sun H, Liu G, McNeel DG, Barnhart TE, Cai W. England CG, et al. Among authors: mcneel dg. J Nucl Med. 2017 Jan;58(1):162-168. doi: 10.2967/jnumed.116.177857. Epub 2016 Aug 4. J Nucl Med. 2017. PMID: 27493273 Free PMC article.

3

DNA vaccines for prostate cancer.

Zahm CD, Colluru VT, McNeel DG. Zahm CD, et al. Among authors: mcneel dg. Pharmacol Ther. 2017 Jun;174:27-42. doi: 10.1016/j.pharmthera.2017.02.016. Epub 2017 Feb 7. Pharmacol Ther. 2017. PMID: 28185916 Free PMC article. Review.

4

Prostate cancer immunotherapy.

McNeel DG. McNeel DG. Curr Opin Urol. 2007 May;17(3):175-81. doi: 10.1097/MOU.0b013e3280eb10eb. Curr Opin Urol. 2007. PMID: 17414515 Review.

5

Androgen deprivation as a tumour-immunomodulating treatment.

Gamat-Huber M, McNeel DG. Gamat-Huber M, et al. Among authors: mcneel dg. Nat Rev Urol. 2020 Jul;17(7):371-372. doi: 10.1038/s41585-020-0328-6. Nat Rev Urol. 2020. PMID: 32355324 No abstract available.

6

Molecular Imaging of Immunotherapy Targets in Cancer.

Ehlerding EB, England CG, McNeel DG, Cai W. Ehlerding EB, et al. Among authors: mcneel dg. J Nucl Med. 2016 Oct;57(10):1487-1492. doi: 10.2967/jnumed.116.177493. Epub 2016 Jul 28. J Nucl Med. 2016. PMID: 27469363 Free PMC article. Review.

7

Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies.

Kelly M, McNeel D, Fisch P, Malkovsky M. Kelly M, et al. Among authors: mcneel d. Immunol Lett. 2018 Jan;193:1-10. doi: 10.1016/j.imlet.2017.11.001. Epub 2017 Nov 10. Immunol Lett. 2018. PMID: 29129721 Review.

8

Cellular immunotherapies for prostate cancer.

McNeel DG. McNeel DG. Biomed Pharmacother. 2007 Jul;61(6):315-22. doi: 10.1016/j.biopha.2006.12.006. Epub 2007 Jan 26. Biomed Pharmacother. 2007. PMID: 17306498 Review.

9

Sipuleucel-T: immunotherapy for advanced prostate cancer.

Olson BM, McNeel DG. Olson BM, et al. Among authors: mcneel dg. Open Access J Urol. 2011 May 3;3:49-60. doi: 10.2147/OAJU.S13069. Open Access J Urol. 2011. PMID: 24198636 Free PMC article. Review.

10

Immune-based therapies for prostate cancer.

McNeel DG, Malkovsky M. McNeel DG, et al. Immunol Lett. 2005 Jan 15;96(1):3-9. doi: 10.1016/j.imlet.2004.06.009. Immunol Lett. 2005. PMID: 15585302 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results